-
EP3897627
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3897627
| EP3897627 - JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL DISEASE [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 07.02.2024 Database last updated on 16.11.2024 | |
| Former | Request for examination was made Status updated on 24.09.2021 | ||
| Former | The international publication has been made Status updated on 02.07.2020 | ||
| Former | unknown Status updated on 08.02.2020 | Most recent event Tooltip | 15.08.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Incyte Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 / US | [2021/43] | Inventor(s) | 01 /
YELESWARAM, Krishnaswamy 1801 Augustine Cut-Off Wilmington, Delaware 19803 / US | 02 /
SMITH, Paul 1801 Augustine Cut-Off Wilmington, Delaware 19803 / US | 03 /
HOLLIS, Gregory F. 1801 Augustine Cut-Off Wilmington, Delaware 19803 / US | [2021/43] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2021/43] | Application number, filing date | 19842939.1 | 19.12.2019 | [2021/43] | WO2019US67418 | Priority number, date | US201862781877P | 19.12.2018 Original published format: US 201862781877 P | US201962854801P | 30.05.2019 Original published format: US 201962854801 P | US201962901377P | 17.09.2019 Original published format: US 201962901377 P | [2021/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020132210 | Date: | 25.06.2020 | Language: | EN | [2020/26] | Type: | A1 Application with search report | No.: | EP3897627 | Date: | 27.10.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.06.2020 takes the place of the publication of the European patent application. | [2021/43] | Search report(s) | International search report - published on: | EP | 25.06.2020 | Classification | IPC: | A61K31/4184, A61P1/00 | [2021/43] | CPC: |
A61K31/4184 (EP,IL);
A61K31/519 (IL,KR,US);
A61K31/4155 (IL,KR,US);
A61K31/437 (IL,US);
A61P1/00 (IL,KR,US);
A61P29/00 (KR)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/43] | Extension states | BA | 13.07.2021 | ME | 13.07.2021 | Validation states | KH | 13.07.2021 | MA | 13.07.2021 | MD | 13.07.2021 | TN | 13.07.2021 | Title | German: | JAK1-WEG-INHIBITOREN ZUR BEHANDLUNG GASTROINTESTINALER ERKRANKUNGEN | [2021/43] | English: | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL DISEASE | [2021/43] | French: | INHIBITEURS DE LA VOIE JAK1 POUR LE TRAITEMENT D'UNE MALADIE GASTRO-INTESTINALE | [2021/43] | Entry into regional phase | 13.07.2021 | National basic fee paid | 13.07.2021 | Designation fee(s) paid | 13.07.2021 | Examination fee paid | Examination procedure | 13.07.2021 | Examination requested [2021/43] | 13.07.2021 | Date on which the examining division has become responsible | 09.02.2022 | Amendment by applicant (claims and/or description) | 19.02.2024 | Despatch of a communication from the examining division (Time limit: M06) | 15.08.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 27.12.2021 | Renewal fee patent year 03 | 27.12.2022 | Renewal fee patent year 04 | 27.12.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]US2017145044 (HUDSON RYAN [US], et al) [I] 1-25 * paragraphs [0003] , [ 107] , [ 140] *; | [I]WO2018111327 (PROGENITY INC [US]) [I] 1-25 * page 10, lines 5-35 * * page 19, line 31 * * page 67, line 11 * * page 109, lines 22-29 *; | [I] - ARGOLLO MARJORIE ET AL, "Novel therapeutic targets for inflammatory bowel disease", JOURNAL OF AUTOIMMUNITY, (20170712), vol. 85, doi:10.1016/J.JAUT.2017.07.004, ISSN 0896-8411, pages 103 - 116, XP085252808 [I] 1-25 * paragraphs [04.1] - [4.1.3] * DOI: http://dx.doi.org/10.1016/j.jaut.2017.07.004 | [I] - SANDBORN WILLIAM J ET AL, "Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis", THE NEW ENGLAND JOURNAL OF MEDICINE, - NEJM -, MASSACHUSETTS MEDICAL SOCIETY, US, (20120731), vol. 367, no. 7, doi:10.1056/NEJMOA1112168, ISSN 0028-4793, pages 616 - 624, XP009503892 [I] 1-25 * Methods * DOI: http://dx.doi.org/10.1056/NEJMoa1112168 | Examination | US2015065484 | by applicant | WO0200196 | US2010298334 | US2011059951 | US2011224190 | US2012149681 | US2012149682 | US2013018034 | US2013045963 | US2013060026 | US2014005166 | US2014121198 | US2014256941 | US2014343030 | US2015065484 | US2015344497 | - SOLBERG et al., Scand. J. Gastroenterol., (20090000), vol. 44, pages 431 - 440 | - LOFTUS et al., Gastroenterology, (20040000), vol. 126, pages 1504 - 1517 | - ANDRES et al., Gastroenterol. Clin. North Am., (19990000), vol. 28, pages 255 - 281 | - SANDBORN et al., N. Engl. J. Med., (20170000), vol. 376, pages 1723 - 1736 | - Remington's Pharmaceutical Sciences, Mack Publishing Company, (19850000), page 1418 | - BERGE et al., J. Pharm. Sci., (19770000), vol. 66, no. 1, pages 1 - 19 | - PARK et al., Analytical Biochemistry, (19990000), vol. 269, pages 94 - 104 | - HEINRICH et al., The Biochemical journal, (20030000), vol. 374, pages 1 - 20 | - ISOMAKI, P et al., Rheumatology, (20150601), vol. 54, no. 6, pages 1103 - 1113 | - Expert Rev Clin Immunol., (20170600), vol. 13, no. 6, pages 535 - 551 | - JDermatolog Treat., (20180900), vol. 29, no. 6, pages 569 - 578 | - ZHOU et al., Nat. Immunol., (20070000), vol. 8, pages 967 - 974 | - HIROTA et al., J. Exp. Med., (20070000), vol. 204, pages 41 - 47 | - CALAUTTI et al., Int JMol Sci., (20180100), vol. 19, no. 1, page 171 | - BISSONNETTE R et al., JDermatolog Treat, (20160000), vol. 27, no. 4, pages 332 - 338 | - MASCARENHAS et al., Haematolgica, (20170000), vol. 102, no. 2, pages 327 - 335 | - KOJIMA et al., J. Pharmacol. Sci., (20040000), vol. 96, no. 3, pages 307 - 313 | - RANDHAWA et al., J. Physiol. Pharmacol., (20140000), vol. 18, no. 4, pages 279 - 288 | - BEATTIE et al., J. Inflamm. (Lond), (20170000), vol. 14, page 28 |